Instituut voor Neuropathische Pijn

Home

JNJ 42160443 from Johnson in neuropathic pain

JNJ 42160443 from Johnson in neuropathic pain, phase II. Hereunder the update of clinical trials running for this compound, as of April 2010. The Janssen compound is a monoclonal antibody directed against nerve growth factor (NGF). In animal models it demonstrates potential analgesic activity. Anti-nerve growth factor monoclonal antibody JNJ-42160443 binds to NGF, and prevents its binding to the NGF receptors TrkA and p75NTR. Inhibition of this pathway may prevent neuropathic pain.

A Trial to Study Pain Relief, Safety, and Tolerability of a New Treatment (JNJ-42160443) for Moderate to Severe Pain of Osteoarthritis of the Knee in Comparison to a Standard Pain Treatment and Placebo

Condition(s): Osteoarthritis; Osteoarthritis, Knee; Pain; Arthralgia; Joint Pain
2

Active, not recruiting

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain

Condition(s): Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain; Arthralgia; Joint Pain
3

Active, not recruiting

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

Condition(s): Low Back Pain; Low Back Pain, Recurrent
4

Recruiting

A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain

Condition(s): Cystitis, Interstitial; Urologic Diseases; Urinary Bladder Diseases; Cystitis
5

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

Condition(s): Pain; Diabetic Neuropathy, Painful
6

Recruiting

A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Condition(s): Pain, Burning; Pain, Crushing; Pain, Migratory; Pain, Radiating; Pain, Splitting
7

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)

Condition(s): Pain; Neuralgia, Postherpetic; Neuralgia; Mononeuropathies.....

From the centre for the study and treatment of neuropathic pain and neuropathy in Soest, the Netherlands

This site helps patients and treating physicians, neurologists, anesthesiologists and other pain specialists to find the best and most up to date research findings related to neuropathy and neuropathic pain and the treatment thereof.

In our centre we are specialised in treating patients suffering from neuropathic pain and neuropathy following an Integrated Medicine concept. Part of our activities are within the field of consultation. We assist pharmaceutical companies in R&D strategies related to finding new drugs to treat neuropathic pain and neuropathy.

April 2010: Jan M. Keppel Hesselink, MD, PhD

Instituut voor Neuropathische Pijn

From the centre for the study and treatment of neuropathic pain and neuropathy in Soest, the Netherlands